Tocilizumab in COVID-19 therapy: who benefits, and how?

Lancet. 2021 Jul 24;398(10297):299-300. doi: 10.1016/S0140-6736(21)01427-6.

¹ Department of Environmental Medicine, Faculty of Medicine, Universitätsklinikum Augsburg, Augsburg, Germany; Institute of Environmental Medicine, Helmholtz Center Munich, Augsburg, Germany. Electronic address: avidan.neumann@uni-a.de.
² Department of Environmental Medicine, Faculty of Medicine, Universitätsklinikum Augsburg, Augsburg, Germany; Environmental Medicine, Technical University Munich, Munich, Germany.
³ Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
⁴ Department of Environmental Medicine, Faculty of Medicine, Universitätsklinikum Augsburg, Augsburg, Germany; Institute of Environmental Medicine, Helmholtz Center Munich, Augsburg, Germany; Environmental Medicine, Technical University Munich, Munich, Germany.
⁵ Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses, Paris, France; Département d'Immunologie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France.

No abstract available

Publication types